Supernus Pharma (SUPN) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Supernus Announces First Quarter 2022 Financial Results
May 9, 2022 4:06 PM EDTFirst quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter 2022, a 38% increase compared to fourth quarter 2021GOCOVRI® prescriptions in first quarter 2022... More
Supernus Announces First Quarter 2022 Financial Results
May 9, 2022 4:05 PM EDTFirst quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter 2022, a 38% increase compared to fourth quarter 2021GOCOVRI® prescriptions in first quarter 2022 reached 10,736, a 23%... More
